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Reports of potential drug-resistant strains of Plasmodium malariae in western Indonesia raise concerns that
chloroquine resistance may be emerging in P. malariae and P. ovale. In order to assess this, in vivo and in vitro
efficacy studies were conducted in patients with monoinfection in Papua, Indonesia. Consecutive patients with
uncomplicated malaria due to P. ovale or P. malariae were enrolled in a prospective clinical trial, provided with
supervised chloroquine treatment, and followed for 28 days. Blood from patients with P. malariae or P. ovale
parasitemia greater than 1,000 per microliter underwent in vitro antimalarial drug susceptibility testing using
a modified schizont maturation assay. Of the 57 evaluable patients in the clinical study (P. malariae, n  46;
P. ovale, n  11), none had recurrence with the same species during follow-up. The mean parasite reduction
ratio at 48 h was 86 (95% confidence interval [CI], 57 to 114) for P. malariae and 150 (95% CI, 54 to 245) for
P. ovale (P  0.18). One patient infected with P. malariae, with 93% of parasites at the trophozoite stage, was
still parasitemic on day 4. In vitro drug susceptibility assays were carried out successfully for 40 isolates (34
infected with P. malariae and 6 with P. ovale). The P. malariae infections at trophozoite stages had significantly
higher chloroquine 50% effective concentrations (EC50s) (median, 127.9 nM [range, 7.9 to 2,980]) than those
initially exposed at the ring stage (median, 14.0 nM [range, 3.5 to 27.0]; P  0.01). The EC50 for chloroquine
in P. ovale was also higher in an isolate initially at the trophozoite stage (23.2 nM) than in the three isolates
predominantly at ring stage (7.8 nM). Chloroquine retains adequate efficacy against P. ovale and P. malariae,
but its marked stage specificity of action may account for reports of delayed parasite clearance times.
Plasmodium malariae and P. ovale exist over much of the
world where malaria is endemic, causing an estimated 60 mil-
lion clinical cases each year (12). Although they account for a
small proportion of all malaria cases (5%), their prevalence
is likely to be underestimated, since they are frequently missed
on routine microscopic blood film examination (4, 6, 11, 22).
Clinical episodes of malariae and ovale malaria are usually
associated with low peripheral parasitemias (1,000 l1),
with the fever classically displaying a periodicity of 3 days for P.
malariae (quartan malaria) and 2 days for P. ovale (tertian
malaria). Chronic, or recurring, parasitemia is more common
following infection with P. malariae or P. ovale than with P.
falciparum. In the case of P. ovale, this is attributable to the
presence of liver stages (hypnozoites) similar to those found in
P. vivax, resulting in relapsing infections, whereas P. malariae is
thought to maintain prolonged subpatent parasitemia (27),
which may cause clinical disease many years after the initial
infection (20). Although generally regarded as benign, chronic
P. malariae and P. ovale infections can result in anemia and, in
the case of the former, an immune complex-mediated ne-
phrotic syndrome.
In Papua, Indonesia, we have been conducting clinical and in
vitro studies to ascertain the efficacy of standard antimalarials
against P. falciparum and P. vivax. This region is unusual in
harboring high levels of drug resistance in both of these spe-
cies; treatment failure within 28 days exceeds 65% after chlo-
roquine (CQ) monotherapy for P. vivax and 48% after chloro-
quine plus sulfadoxine plus pyrimethamine for P. falciparum
(7, 16, 21). The high levels of chloroquine resistance in P.
falciparum and P. vivax, coupled with previous observations of
potential drug-resistant strains of P. malariae in western Indo-
nesia (10), raised concerns that chloroquine resistance might
also be emerging in P. malariae and P. ovale. The aim of the
present study was to define the in vivo and in vitro efficacy of
chloroquine in these species.
MATERIALS AND METHODS
Study site. The study was carried out in Timika, Papua, Indonesia. The malaria
epidemiology of this region has been reported previously (8). In brief, the
forested lowland area has unstable malaria transmission associated with three
mosquito vectors: Anopheles koliensis, Anopheles farauti, and Anopheles punctu-
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Research, P.O. Box 41096, Casuarina, Darwin, NT 0811, Australia.
Phone: (61) 8 8922 8197. Fax: (61) 8 8922 8429. E-mail: rprice
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latus (9, 14). The annual incidence of malaria is estimated to be 876 per 1,000 per
year, with 90% of infections attributable to P. falciparum (55%) and P. vivax
(45%) (8). Over a 5-year period (2004 to 2009), P. malariae accounted for 2,059
(2.9%) of 71,184 outpatient consultations for malaria at the local Rumah Sakit
Mitra Masyarakat Hospital and 281 (1.5%) of 18,172 admissions with malaria
(unpublished data). The corresponding figures for P. ovale were 72 and 6 cases.
The ethnic origin of the local population is diverse, with highland Papuans,
lowland Papuans, and non-Papuans all resident in the region. In view of the high
number of infections in nonimmune patients, local protocols recommend that all
patients with patent parasitemia be given antimalarial therapy irrespective of
whether they have symptoms.
Clinical study. The clinical study was based on the 2003 World Health Orga-
nization (WHO) in vivo antimalarial drug sensitivity protocol (29) and was
conducted in a rural outpatient clinic 10 km from the town center between July
2004 and August 2005. Consecutive patients with slide-confirmed malaria due to
any species and fever or a history of fever during the preceding 48 h presenting
at the clinic were enrolled in the study if they or their parents gave informed
consent. Pregnant or lactating women, children under 10 kg body weight, and
patients with signs of severity (30), a parasitemia of4%, or concomitant disease
requiring hospital admission were all excluded. Inclusion or exclusion in the
clinical study was not based on the stage distribution of the parasite on the blood
film.
Study procedures. On admission, a standardized questionnaire was completed
recording demographic information, details of symptoms and their duration, and
the history of previous antimalarial medication. A full clinical examination was
made, and the axillary temperature was measured using a digital electronic
thermometer. Blood was taken for blood film, hematocrit, and white blood cell
(WBC) count. Parasite counts were determined on Giemsa-stained thick films as
the number of parasites per 200 WBCs. All slides were read by an expert
microscopist with at least 10 years of experience. A thick smear was considered
negative on initial review if no parasites were seen in 100 high-power fields. A
thin smear was also examined to confirm the parasite species and was used for
quantification if parasitemia was greater than 200 per 200 WBCs. All slides were
cross-checked by another experienced microscopist. Upon cross-checking, the
whole field was checked before a slide was considered negative.
Patients were examined daily thereafter until they became afebrile and apara-
sitemic. At each visit, a blood smear was taken and a symptom questionnaire was
completed. Patients were then seen weekly, or on any other day when the patient
was sick, for 4 weeks. At each clinic appointment, a full physical examination was
performed, the symptom questionnaire was completed, and blood was taken to
check the parasite count and hemoglobin level using a battery-operated portable
photometer (HemoCue Hb201). Blood spots on filter paper (Whatman 3MM
Chromatography Paper) were also collected on day 0 and the day of failure.
Treatment. Standard treatment courses of CQ (PT Bayer, Jakarta, Indonesia;
150 mg base/tablet; 25 mg/kg over 3 days) were administered for P. ovale or P.
malariae infections. All drug administrations were supervised, and participants
were observed for 30 to 60 min to exclude adverse reactions and to ensure the
medication was not vomited. If vomiting occurred within 60 min, the whole dose
was repeated once. If vomiting occurred again within 60 min, the patient was
withdrawn from the study. If the axillary temperature was 38°C, paracetamol
was given.
Recurrent parasitemias occurring during follow-up were re-treated with qui-
nine (10 mg of salt/kg body weight/dose orally three times a day for 7 days) plus
doxycycline (100 mg twice daily for 7 days) if the patient was more than 8 years
old. Primaquine (0.5 mg of base/kg of body weight for 14 days) was administered
to those individuals with P. ovale infection on day 28 of their participation in the
study.
In vitro study. Patients with symptomatic malaria presenting at the outpatient
clinic of the local Rumah Sakit Mitra Masayarat (RSMM) were recruited into
the study if singly infected with P. malariae or P. ovale with a parasitemia greater
than 1,000 per microliter. After 2008, parasites for the in vitro assay were selected
from those at majority ring stage. Patients treated with antimalarials in the
previous 3 weeks were excluded from the study. Since patients were not enrolled
in clinical studies, the therapeutic response to treatment could not be deter-
mined.
In vitro drug susceptibility assay. The antimalarial susceptibilities of P. ovale
and P. malariae isolates were measured using a protocol modified from the WHO
microtest, as described previously (18). Venous blood (5 ml) was collected by
venipuncture, and after removal of host white blood cells using a CF11 column,
2 ml of packed infected red blood cells (IRBC) were divided as follows: 1 ml was
cryopreserved in glycerolyte, 200 l was spotted onto filter paper, and 800 l was
used for the in vitro drug susceptibility assay. Two hundred microliters of a 2%
hematocrit blood medium mixture (BMM) consisting of McCoy’s 5A medium
and 20% AB human serum was added to each well of predosed drug plates; the
drug plates contained 11 serial concentrations (2-fold dilutions) of the antima-
larials, with maximum concentrations of 5,910 nM for chloroquine, 557 nM for
amodiaquine, 93 nM for artesunate, 338 nM for mefloquine, 87 nM for pyrona-
radine, and 769 nM for piperaquine. A candle jar was used to mature the
parasites at 37.5°C for 15 to 56 h. Incubation was stopped when 40% of ring
stage parasites had matured into mature schizonts in the drug-free control.
Preliminary studies demonstrated that once the 40% schizont threshold had been
reached, further incubation did not increase the final count.
Thick blood films made from each well were stained with 5% Giemsa solution
for 30 min and examined microscopically. Differential counts of 200 asexual
parasites in both the preincubation and test slides were classified into ring stage
(ring-shaped trophozoites without pigment), mature trophozoites (single or dou-
ble chromatin dots and hemazoin pigment visible), and schizonts. To ensure
optimal maturity, ease of parasite identification, and reduction of parasite clas-
sification errors between microscopists, only schizonts with at least five well-
defined chromatin dots were classified as schizonts at harvest. Free merozoites
and gametocytes were not included in the count. The number of schizonts (5
chromatin dots visible) per 200 asexual-stage parasites was determined for each
drug concentration and normalized to the drug-free control well. The dose-
response data were analyzed using nonlinear regression analysis (WinNonLin
4.1; Pharsight Corporation), and the 50% inhibitory concentration (IC50) was
derived using an inhibitory sigmoid Emax model. Only IC50 in vitro data from
predicted curves where the maximum (Emax) and minimum (E0) were within
15% of 100 or 0, respectively, were used.
Confirmation of Plasmodium species. A multiplex PCR was used to confirm
Plasmodium species for pretreatment and recurrent isolates in the clinical study
and isolates in the in vitro study prior to starting culture (13). For these isolates,
genomic DNA from blood spots was extracted using a QIAamp DNA Mini Kit
(Qiagen, Doncaster, Australia).
Statistical analysis. Data were double entered and validated using EpiData
3.02 software (EpiData Association, Odense, Denmark), and analysis was per-
formed using SPSS for Windows version 14 (SPSS Inc., Chicago, IL). The
Mann-Whitney U test or Kruskal-Wallis method was used for nonparametric
comparisons and Student’s t test or one-way analysis of variance for parametric
comparisons. For categorical variables, percentages and corresponding 95% con-
fidence intervals were calculated using Wilson’s method. Proportions were ex-
amined using 2 with Yates’ correction or by Fisher’s exact test.
Treatment efficacy, as gauged by both the risk of recurrence and the rate of
parasite clearance, was assessed using a modified intention-to-treat analysis. The
evaluable population was defined as all patients in whom monoinfection by P.
malariae and P. ovale could be confirmed. The risk of recurrent infection was
derived by survival analysis, with the cumulative risk of failure calculated by the
Kaplan-Meier product limit formula. Data were censored on the last day of
follow-up for patients with protocol violations (e.g., incomplete treatment or lost
to follow-up) or re-presenting with a peripheral parasitemia other than P. ma-
lariae and P. ovale.
Ethics. The study was approved by the Ethics committee of the National
Institute of Health Research and Development, the Indonesian Ministry of
Health (Jakarta, Indonesia), and the Ethics Committee of Menzies School of
Health Research (Darwin, Australia). Informed consent was obtained from all
adult participants and from the parents of children. Informed consent was sought
from all patients, or their parent/guardian, in their own language.
RESULTS
Clinical study. Between April 2004 and August 2005, 69
patients were enrolled in the clinical study. Microscopy cross-
checking and PCR analysis revealed 12 protocol violations (7
in the P. malariae arm and 5 in the P. ovale arm); these patients
were removed from further analysis (Fig. 1). The baseline
characteristics of the remaining 57 patients in the evaluable
population (P. malariae, n  46; P. ovale, n  11) are given in
Table 1. Compared to patients infected with P. ovale, those
infected with P. malariae were younger (P  0.014) and had
lower hemoglobin levels on enrollment (P  0.001) (Table 1).
Although all patients had a history of fever, only 15% (7/46) of
P. malariae patients and 18% (2/11) of P. ovale patients had a
recorded fever at enrollment. At presentation, patients with P.
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malariae or P. ovale infections had low parasitemias (median 
633 l1 and 645 l1, respectively), with asexual stages pre-
dominantly at the trophozoite stage; the median percentages
of trophozoites were 99% (range, 66% to 100%) for P. ma-
lariae and 98% (range, 92% to 100%) for P. ovale.
A 2-year-old female and a 3-year-old male in the P. malariae
group had recurrent vomiting of chloroquine syrup on admis-
sion and were referred to the hospital for intravenous quinine.
They made a full and unremarkable recovery. Four patients, all
in the P. malariae arm, failed to return to the clinic for super-
vised therapy. The remaining 51 patients completed a full
course of chloroquine, and none vomited their drug. The me-
dian dose of chloroquine administered was 26.1 (range, 20.6 to
33.3) mg/kg in the P. malariae group and 27.7 (range, 23.0 to
37.3) mg/kg in the P. ovale group.
Therapeutic response. All 11 of the patients infected with P.
ovale had defervesced within 24 h and were aparasitemic within
48 h. Six patients with P. malariae infection did not complete
treatment, and blood films on day 2 were not available for an
additional 3 patients. Of the remaining 37 patients, 7 (18.9%)
were still parasitemic at 48 h, 1 of whom was febrile. Of these
seven patients, one had cleared by day 3 and another five did
not return for follow-up until day 7, when all were noted to be
aparasitemic. The remaining patient, with an initial para-
sitemia of 675 l1 with 93% trophozoites, was still para-
sitemic on day 4 but was observed to be aparasitemic on day 11.
The mean parasite reduction ratio at 48 h was 86 (95% confi-
dence interval [CI], 57 to 114) for P. malariae and 150 (95% CI,
54 to 245) for P. ovale; P  0.18.
In total, 6 patients infected with P. malariae (15%) and 3
infected with P. ovale (27%) did not complete 28 days of
follow-up. In the P. malariae group, 13 patients had recurrent
malaria (3 infected with P. falciparum, 8 infected with P. vivax,
and 2 with mixed infections, all confirmed by PCR). Recurrent
infection due to any species occurred a median of 21 (range, 14
to 28) days after treatment, with a day 28 cumulative risk of
recurrence of 39% (95% CI, 22% to 56%). There were no
recurrent infections with P. malariae, the cure rate being 100%
(95% CI, 84.5% to 100%). In the P. ovale group, 2 patients had
recurrent malaria due to P. vivax (at days 14 and 23), with an
overall day 28 cumulative risk of recurrence of 23% (95% CI,
0% to 51%) and a P. ovale cure rate of 100% (95% CI, 61% to
100%).
Gametocyte carriage and anemia. On admission, gameto-
cytes were present in 26% (12/46) of patients infected with P.
malariae and 46% (5/11) of patients infected with P. ovale (P
0.16). None of the patients had P. malariae or P. ovale game-
tocytes during follow-up. On admission, 67% (31/46) of pa-
tients infected with P. malariae were anemic compared to 36%
(4/11) of patients infected with P. ovale (P  0.09). In those
followed until day 28, these proportions had fallen to 22%
(2/9) and 0% (0/2), respectively.
In vitro study. Between January 2005 and February 2008, 62
isolates from patients with single-species infections by either P.
malariae (n 46) or P. ovale (n 16) were assessed for in vitro
susceptibility (Fig. 2). The infecting species was confirmed by
PCR in all but one isolate (initially processed as P. ovale, it was
found to be P. vivax by molecular analysis). Susceptibility pro-
files were tested against chloroquine, amodiaquine, artesunate,
mefloquine, pyronaridine, and piperaquine. The baseline char-
FIG. 1. Study profile of the clinical study.
TABLE 1. Patient characteristics at baseline
Characteristic of species at enrollment
Value
P. malariae P. ovale
No. in evaluable population 46 11
Geometric mean parasitemia (l1) (95% CI), range 633 (459–863), 51–10,350 645 (247–1,686), 29–3,225
Males n (%)	 29 (63) 8 (73)
Age (yr) median (range)	 13.5 (2–38) 28 (5–53)
5 yr n (%)	 6 (13) 0 (0)
5–14 yr n (%)	 19 (41) 2 (18)
14 yr n (%)	 21 (46) 9 (82)
Temp (°C) 37.5 n (%)	 7 (15) 2 (18)
Hemoglobin (g/dl) mean (SD)	 9.5 (2.0) 12.2 (3.1)
Anemia (Hb  10 g/dl) n (%)	 31 (67) 4 (36)
Gametocyte carriage on admission n (%)	 12 (26) 5 (46)
Splenomegaly n (%)	 39 (85) 8 (73)
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acteristics of the isolates processed are presented in Table 2.
Asexual parasitemias of both P. malariae and P. ovale infec-
tions revealed mixed stages in the peripheral blood. Whereas
P. malariae isolates were mostly at trophozoite stages (median,
80% [range, 13% to 100%] trophozoites), P. ovale isolates in
the in vitro study were mostly at the ring stage (median, 98%
[2% to 100%] rings). Adequate growth for harvest was
achieved in 77% (37/48) of P. malariae isolates and 60% (9/15)
of P. ovale isolates. The time taken to reach the threshold for
harvest was significantly longer for P. malariae isolates (me-
dian, 45 [range, 24 to 72] h) compared to P. ovale (median, 38
[range, 29 to 43] h); P  0.05.
Our previous studies have highlighted the effects of infec-
tions with mixed asexual-stage infections on the derived drug
susceptibility profile in P. vivax (18, 19). For this reason, the
geometric mean IC50s for P. malariae and P. ovale are pre-
sented after stratifying them by whether infections were at
majority ring or trophozoite stage (Table 3). P. malariae infec-
tions at trophozoite stages had chloroquine 50% effective con-
centrations (EC50s) (median, 127.9 [range, 7.9 to 2,980] nM)
significantly higher than those initially exposed at ring stage
(median, 14.0 [range, 3.5 to 27.0] nM; P  0.01). This stage-
specific activity was not apparent for any of the other drugs
tested. The EC50 for chloroquine in P. ovale was also higher in
an isolate initially at the trophozoite stage (23.2 nM) than in
the three isolates predominantly at ring stage (7.8 nM).
DISCUSSION
Drug-resistant strains of P. falciparum and P. vivax are now
increasingly recognized throughout the world (1, 28), but few
studies have addressed the clinical or in vitro efficacy of anti-
malarials against minor Plasmodium species. This is a likely
consequence of their perceived importance, the lack of signif-
icant patient numbers available to be recruited into clinical
trials, and an inability to sustain the parasites in continuous in
vitro culture. In Papua, our clinical study, although with a
limited sample size, found that all patients enrolled with either
P. malariae or P. ovale infections responded to chloroquine
therapy. Almost a third of patients had recurrent parasitemia
within 28 days, but all of these were due to P. falciparum or P.
vivax (confirmed by PCR), reflecting the known high levels of
drug resistance in these species in this area (16). Infections due
to low-grade drug-resistant isolates treated with a slowly elim-
inated antimalarial drug can lead to recrudescent infections as
late as 63 days following initial treatment (25). The duration of
follow-up in our study was limited to 28 days, and we cannot
rule out the occurrence of late recrudescence. However, the
lack of any recurrences within 28 days is reassuring and sug-
gests that if chloroquine resistance is emerging, for the time
being it has not reached a high level. Patients with ovale ma-
laria responded rapidly to treatment, with all patients afebrile
within 24 h and aparasitemic within 48 h. In contrast, the
FIG. 2. Study profile of the in vitro study.
TABLE 2. Characteristics of isolates with successful in vitro susceptibility assays
Baseline characteristic
Value
P. malariae P. ovale
Total no. of isolates reaching successful assay 34 6
Median (range) delay from venipuncture to start of culture (h) 1.96 (0.75–4.08) 1.88 (1.67–3.92)
Median (range) duration of assay (h) 45 (24–72) 38 (29–43)
Geometric mean (95% CI) parasitemia (no. of asexual parasites/l) 2,861 (2,244–3,648) 2,736 (2,026–3,694)
Mean (95% CI) schizont count at harvest 47 (42–52) 39 (30–49)
Median initial % (range) of parasites at ring stage 20 (0–87) 98 (2–100)
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clinical response in patients with P. malariae infection was
significantly slower, with almost 20% of patients still para-
sitemic by hour 48 and one patient remaining parasitemic on
day 4. Similar observations have been reported from Madagas-
car, where a patient treated with chloroquine still had P. ma-
lariae detected by PCR on day 7, although it was subsequently
cleared with no late recurrence (2). In P. falciparum and P.
vivax infections, delayed parasite clearance is associated with a
significantly greater risk of recurrence within 28 days and thus
can be used as a useful marker of emerging parasite resistance
(16, 26). However, the same may not be true of P. malariae.
The slow early response of P. malariae to chloroquine was first
documented by Young and Eyles in 1948 (31) and again by
Collins and Jeffery in their retrospective analysis of archival
data for patients treated with chloroquine between 1949 and
1963 (5). In the latter case series, 20% of patients were still
parasitemic at day 7, a proportion that was apparently unre-
lated to the starting parasitemia. Although Maguire and col-
leagues raised concerns about the emergence of chloroquine-
resistant P. malariae in Sumatra, Indonesia, in their clinical
study in 2000 (10), this rested on observations of 2 patients out
of 28 who were still parasitemic on day 8, along with a patient
who rapidly cleared the initial infection but who had a subse-
quent recurrence on day 28. This could have been a reinfec-
tion.
The delay in the clearance of P. malariae following chloro-
quine may be attributable to factors other than parasite resis-
tance. Clinical infections with P. falciparum are usually present
in the peripheral circulation, with parasites predominantly at
ring stage. In contrast, in P. vivax, P. malariae, and P. ovale
infections, all stages of the parasite are present in the periph-
eral blood. The distribution of parasite stages varies between
areas of differing endemicity, a factor that confounds the in-
terpretation of in vitro susceptibility to chloroquine in both
Thai and Indonesian isolates (18, 19). Chloroquine efficacy is
significantly reduced against P. vivax trophozoites, and this is
apparent in isolates from both chloroquine-sensitive (19) and
-resistant populations (18), suggesting an intrinsic difference in
stage-specific drug activity between species rather than one
acquired due to chloroquine resistance.
The published literature of in vitro drug susceptibility in P.
malariae and P. ovale is limited to no more than a few studies
reporting a total of 20 isolates (3, 17, 23, 24). Overall, the
derived chloroquine IC50s in our study were similar to those
reported previously, although when analysis was restricted to
parasites initially exposed to the drug at ring stage, our derived
IC50s were a log order lower. Analysis of our P. malariae in
vitro data revealed a significant confounding effect of the stage
of the parasite, with isolates predominantly at ring stage having
9-fold-higher IC50s of chloroquine than parasites initially at
trophozoite stage (median, 14 nM versus 128 nM). This differ-
ence was not observed for any of the other antimalarial drugs
tested or for the P. ovale assay (although the number of isolates
tested was low).
Our clinical and in vitro assessments of drug efficacy were
not conducted simultaneously, so we are unable to correlate
the in vitro and in vivo parasite responses directly. However,
the absence of any P. malariae or P. ovale recurrences within 28
days in our clinical study, in conjunction with the in vitro data
for isolates tested initially at ring stage (all had IC50s below 27
nM), suggests that in this region both species remain intrinsi-
cally susceptible to chloroquine. The patient infected with P.
malariae who was still parasitemic on day 4 had a relatively
high initial parasitemia on admission (1,184 l1, 93% of
which were at the trophozoite stage). We estimate that the
parasite reduction ratio at 48 h (defined as the parasitemia on
admission divided by the parasitemia at day 2) is approximately
100 for P. malariae and 150 for P. ovale. These figures compare
with estimates of 103 to 104 for chloroquine in sensitive isolates
of P. falciparum and P. vivax (15, 26). A peripheral parasitemia
of 1,000 l1 corresponds to a total biomass of about 1010. To
reduce this to a level undetectable by microscopy (
108 total
parasite biomass) requires parasite exposure to drug for at
least one life cycle. In the case of chloroquine and P. malariae,
this needs to be longer if the initial parasite load is predomi-
nantly present at the innately resistant trophozoite stage. The
life cycle of P. malariae is 72 h compared to 24 to 48 h for the
other human Plasmodium species. In this context, clearance of
P. malariae parasitemia within 4.5 days is to be expected rather
than being indicative of declining drug efficacy. For clearance
times longer than this, one would need to evoke other factors,
such as a high parasitemia at presentation or partial drug
absorption.
In conclusion, our studies show no evidence of declining
chloroquine efficacy against P. ovale and P. malariae in Papua.
The marked difference in the antimalarial activities of chloro-
quine against trophozoite and ring stage parasites in P. vivax, P.
malariae, and perhaps P. ovale raises important questions re-
TABLE 3. In vitro susceptibility of each drug according to species tested
Drug
P. malariae P. ovale
Majority trophozoites Majority rings Majoritytrophozoites Majority rings
na Median IC50b (range) n Median IC50 (range) n IC50 n Median IC50 (range)
Chloroquine 23 127.9 (7.9–2980) 7 14.0c (3.5–27.0) 1 23.2 3 7.8 (3.3–17.3)
Amodiaquine 20 19.1 (2.5–96.4) 9 21.7 (2.8–40.3) 0 5 4.3 (1.0–12.8)
Artesunate 17 2.84 (0.15–15.8) 7 1.77 (0.27–9.3) 1 1.28 4 1.16 (0.17–2.85)
Mefloquine 19 46.9 (9.8–336.9) 6 36.8 (4.8–164.0) 0 5 23.8 (6.2–49.9)
Pyronaridine 13 7.8 (0.1–150) 2 4.1 (0.53–7.6) 0 3 0.72 (0.17–1.39)
Piperaquine 22 38.4 (6.3–698) 8 29.0 (6.6–35.9) 1 7.57 5 10.2 (4.7–15.5)
a n, number of assays with acceptable IC50 data.
b IC50s are given in nM concentrations.
c P  0.01, comparing IC50s in isolates with majority trophozoites to those with majority rings.
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garding the pharmacodynamic antimalarial properties of chlo-
roquine (19). Further studies are required to elucidate this, as
well as the relevance of parasite staging for the clinical re-
sponse to chloroquine of non-falciparum parasites.
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